Description
Filorexant, a selective reversible and orally bioavaliable antagonist of OX(1)R receptor and OX(2)R receptor, could probably be an effective compound in the treatment of insomnia. It is still under the Phase II trial by Merck. Binding Ki: less than 3 nM